Brigatinib for NF2 Neurofibromatosis: Mechanism, Efficacy and Prospects

　　Brigatinib has demonstrated clear clinical value in the treatment of Neurofibromatosis Type 2(NF2).The drug works by targeting cell signaling pathways abnormally activated after Merlin protein function loss caused by NF2 gene mutations,particularly the EGFR pathway,effectively inhibiting key drivers of tumor proliferation.Both theoretical research and clinical practice have confirmed its ability to slow or even halt the growth of NF2-related tumors.

　　I.Mechanism of Action and Clinical Evidence

　　Brigatinib's therapeutic effect on NF2 stems from its unique mechanism.NF2 pathogenesis is closely related to Merlin protein deficiency.When this tumor suppressor protein becomes inactive,it leads to uncontrolled cell growth,with the EGFR signaling pathway playing a key driving role in this process.Brigatinib,as a potent tyrosine kinase inhibitor,was originally used to treat non-small cell lung cancer,but its multi-target inhibition characteristics enable it to precisely act on key kinases such as EGFR,directly intervening in NF2 tumor growth.

　　This scientific hypothesis has been validated in preclinical studies and strongly supported in human clinical trials.A Phase II clinical trial published in The Lancet Oncology showed that brigatinib demonstrated significant objective response rates in treating progressive NF2-related tumors,with patients experiencing clinically meaningful tumor shrinkage.More notably,the study observed hearing stabilization or even improvement in some patients who retained hearing,which is a milestone for NF2 patients whose main concern is hearing loss.Although treatment was accompanied by controllable side effects such as elevated serum amylase and hypertension,the overall efficacy has opened new directions for NF2 drug therapy.

　　II.Treatment Prospects and Challenges

　　Brigatinib has broad application prospects in the NF2 treatment field,but converting this potential into routine clinical practice requires overcoming multiple challenges:

　　Side Effect Management:As a potent targeted drug,careful dose adjustment and supportive symptomatic treatment are needed to balance efficacy with patient quality of life.

　　Long-term Efficacy and Resistance:Current studies have limited follow-up time.Whether brigatinib can achieve long-term tumor control and whether patients will inevitably develop resistance are key issues determining its therapeutic position.

　　Patient Selection:How to identify patient populations most sensitive to brigatinib to achieve individualized precision therapy is an important direction for future research.

　　Drug Accessibility:Due to high costs and lack of formal approval by global regulatory agencies for NF2 indications,patient access is limited,often relying on clinical trials or off-label use,which greatly restricts its widespread application.

　　Future research will focus on optimizing dosing regimens,exploring combination therapies to overcome resistance,and actively promoting formal drug approval,enabling this promising treatment to truly benefit the broad NF2 patient population.During treatment,patients must maintain close communication with professional medical teams,comprehensively assess their condition,make appropriate treatment decisions after weighing pros and cons,and monitor any abnormal reactions during treatment and seek medical attention promptly to ensure treatment safety and effectiveness.